Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy by Hardiansyah, Deni & Ng, Chee Meng
Follow this and additional works at: https://uknowledge.uky.edu/ps_facpub 
 Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Translational Medical 
Research Commons 
University of Kentucky 
UKnowledge 
Pharmaceutical Sciences Faculty Publications Pharmaceutical Sciences 
7-2019 
Quantitative Systems Pharmacology Model of Chimeric Antigen 
Receptor T-Cell Therapy 
Deni Hardiansyah 
University of Kentucky 
Chee Meng Ng 
University of Kentucky, chee.ng@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy 
Notes/Citation Information 
Published in Clinical and Translational Science, v. 12, issue 4, p. 343-349. 
© 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of 
the American Society for Clinical Pharmacology and Therapeutics. 
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial 
License, which permits use, distribution and reproduction in any medium, provided the original work is 
properly cited and is not used for commercial purposes. 
Digital Object Identifier (DOI) 
https://doi.org/10.1111/cts.12636 
This article is available at UKnowledge: https://uknowledge.uky.edu/ps_facpub/143 
Citation: Clin. Transl. Sci. (2019) 12, 343–349; doi:10.1111/cts.12636
BRIEF REPORT
Quantitative Systems Pharmacology Model of Chimeric 
Antigen Receptor T-Cell Therapy
Deni Hardiansyah1 and Chee Meng Ng1*
Chimeric antigen receptor T- cell (CART) therapy is a new and promising cancer therapy. However, severe toxicity due to cy-
tokine release syndrome (CRS) in CART- treated patients highlighted the possible danger of this new therapy. Disease burden 
and CART doses are the potential factors associated with CRS but the detail relationships between these factors and the 
severity of the CRS remain largely unknown. In this study, the quantitative systems pharmacology (QSP) approach is used to 
quantify the complex relationships among CART doses, disease burden, and pro inflammatory cytokines in human subjects 
and to gain relevant insights into the determinant of clinical toxicity/efficacy in development of CART therapy. The expansion 
of CART and elimination of B  cells are more highly correlated with disease burden than the administered CART doses. To our 
best knowledge, this is the first QSP model that can describe the observed clinical data from CART- treated patients with 
cancer. This QSP model is a valuable tool for deepening our understanding of how the mechanism of action connects to the 
clinical outcomes and, therefore, may serve as an important model- based platform to guide the development and personal-
ized dosing of the CART therapy.
Chimeric antigen receptor T  cells (CART) are engineered 
 T  cells with a single- chain variable fragment on the cell 
membrane that recognizes the tumor antigen and intracel-
lular signaling domain that can promote T  cells’ antitumor 
function.1,2 CART therapy demonstrates remarkable efficacy 
in some blood cancers and represents a paradigm shift 
in oncology treatment.2–6 Currently, two anti- CD19 CART 
therapies have been approved by the US Food and Drug 
Administration: tisagenlecleucel- T (Kymriah; Norvatis) for 
pediatric and young adults (up to 25 years) with relapsed 
or refractory B- cell acute lymphoblastic leukemia (ALL) 
and axicabtagene ciloleucel (Yescarta; Kite Pharma/Gilead 
Sciences) for adults with relapsed or refractory B- cells lym-
phoma, including diffuse large B- cell lymphoma.2–4 The 
CART therapy pipeline is rapidly expanding and is expected 
to capture the largest share of drug sales in pediatric and 
young adult patients with ALL and diffuse large B- cell lym-
phoma.2 However, unexpected organ damage and deaths 
following CART therapy have been reported and, thus, high-
light the possible danger of this new treatment.1 Cytokine 
release syndrome (CRS), a systemic inflammatory response 
caused by pro inflammatory cytokines released by infused 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Chimeric antigen receptor T cell (CART) therapy is a new 
and promising therapy for cancer. However, unexpected 
toxicity, such as cytokine release syndrome (CRS), follow-
ing CART therapy can cause significant organ dysfunction 
and death. The disease burden and CART doses have 
been proposed to be associated with the CRS, but the 
quantitative relationships between these factors and the 
CRS associated with CART therapy remain largely 
unknown.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  We built the first quantitative systems pharmacology 
(QSP) model that can describe the complex relationships 
of CART and pro inflammatory cytokines associated with 
CRS for CART therapy. By using this model, we have 
quantified relationships among CART dose, disease bur-
den, and CRS associated with CART therapy.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  This study shows that CART is a “living drug” that exhibits 
unique target- mediated drug disposition characteristics (i.e., 
the CART cells “live and grow” in the presence of the target 
cells), which is in contrast to most drugs that accelerate the 
elimination from the body after binding to the targeted recep-
tors. Furthermore, the magnitude of the inflammatory  cytokine 
(e.g., interleukin (IL- 6), IL- 10, and interferon γ) elevation is 
more related with baseline disease burden than the adminis-
tered doses.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCES?
✔  This QSP model is a valuable tool for deepening our 
understanding of how the mechanism of action connects 
to the clinical outcomes and, therefore, may serve as an 
important model- based platform to guide the development 
and personalized dosing of the CART therapy.
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CART, is the major and most common source of toxicity that 
can cause widespread significant organ dysfunction and 
death.1,3,7 As a result, both tisagenlecleucel- T and axicabta-
gene ciloleucel are available through a restricted program 
that includes a risk evaluation mitigation strategy to address 
the severe and life- threatening toxicity of CRS.2 Although 
potential risk factors, such as disease burden (DB), CART 
doses, and T- cell expansion levels after CART infusion, are 
expected to be associated with the severity of the CRS, the 
quantitative relationships between these factors and the se-
verity of the CRS reported in CART- treated patients remains 
largely unknown.1 Therefore, further investigation is needed 
to elucidate the quantitative relationship of CRS and the DB/
CART dose in order to design an optimal dosing strategy for 
the prevention of the CRS. Recently, several mathematical 
models have been developed to provide theoretical spec-
ulation for the biologic of CART therapy, but none of these 
models has been used to describe the kinetic profiles of 
pro inflammatory cytokine and CART observed in patients 
with cancer treated with CART.8–10 Hence, in this study, we 
develop the first quantitative systems pharmacology (QSP) 
model that can describe the observed kinetic profiles of 
CART, DB, and pro inflammatory cytokines in a patient with 
advanced chronic lymphocytic leukemia (CLL) treated with 
anti- CD19 CART therapy.
METHODS
Distinct kinetic profiles of the CART and inflammatory 
 cytokines (interleukin- 6 (IL- 6), IL- 10, and interferon gamma 
(IFN γ) in peripheral blood (PB) from two patients with CLL 
were used to develop the QSP model (Figure 1a). Kinetic 
data of pro inflammatory cytokines were obtained from the 
supplemental tables in Kalos et al.,7 and the kinetic data 
of CART were obtained from the same study using soft-
ware WebPlotDigitizer (version 3.8; https://automeris.io/
WebPlotDigitizer/). The clinical study was conducted ac-
cording to the guidelines described in the Declaration of 
Helsinki, and detailed information about the study design 
has been reported previously.7 In brief, three patients with 
advanced, chemotherapy- resistant CLL were enrolled in 
the study and the treatments were scheduled as an i.v. dose 
of CART cells with 3- day split dose regimen (10%, 30%, 
and 60%). Corticosteroid therapy can inhibit the expression 
and action of most cytokine.11 UPN2 was excluded from the 
analysis because this patient had a different and subdued 
CART and cytokine kinetic profile compared with the other 
two subjects (UPN1 and UPN3),7 which was possibly due to 
the cytokine- masking effects of concurrent corticosteroid 
treatment. As a result, only two subjects (UPN1 and UPN3) 
were included in the QSP model development in this study.
The IL- 6, IL- 10, and IFN- γ were selected because these 
cytokines played an important role in the inflammatory re-
sponses. Elevation of these pro inflammatory cytokines was 
associated with the severity of CRS and other toxicities after 
CART infusion.1,12 Figure 1a shows the developed QSP 
model based on the current understanding of the complex 
interactions among CART, B  cells, IL- 6, IL- 10, and IFN γ in 
human subjects. The detailed description of the QSP model 
implementation is included in the Supplementary File. In 
brief, CART was divided into two phenotypes of T cells (i.e., 
activated/effector (CARTE) and memory T cells (CARTM). 
Injected CART were assumed to be activated after interact-
ing with CLL B-cells and were expanded via growth rate rE. 
CARTE was eliminated from the body with death rate dCARTE. 
Activated CART were converted into long- life CARTM via ac-
tivation rate aE, which related to the CLL B-cells saturation 
function f(B). On the other hand, during the fast expansion 
of CARTE, CARTM were converted into short- life CARTE to 
kill the CLL cancer via activation rate aM. CARTM were ex-
panded via natural growth rate rM and were eliminated from 
the body with death rate dCARTM. Distribution of both CARTE 
and CARTM between PB and tissue was described by the 
rate constants kin and kout.
The B cells in patients with CLL were assumed to have 
exponential growth with production rate rB and natural death 
rate dB in PB. Activated CARTE cells killed the B  cells via kill-
ing rate KBC and secreted IL- 6, IL- 10, and IFN γ into the blood 
to induce the inflammatory responses and CRS. The baseline 
cytokine levels in patients with CLL before  anti- CD19 CART 
therapy were maintained with the endogenous synthesis rate 
of Pendo IL6, Pendo IL10, and Pendo IFNγ, and natural death rate of 
dIL6, dIL10, and dIFNγ for IL- 6, IL- 10, and IFN γ, respectively. 
Known inhibitory effects of IL- 10 on the secretion of IFN γ by 
activated T cells was included in the model. Most model pa-
rameters were obtained from the published literature (Table 
S1) except for several CART- related parameters that had 
never been reported in the literature and, therefore, had to 
be estimated by fitting the QSP model to all observed data 
simultaneously. These CART- related parameters included 
CART- induced  IL- 6, IL- 10, and IFN γ secretion (PIL6, PIL10, 
and PINFγ), growth rate of CARTE cells (rE), the killing rate 
of CARTE cells to B cell CLL in PB (KBC), activation rate aM, 
and CARTE death rate dCARTE.
The ability of the final QSP model in describing the rela-
tionships between disease burden/CART doses and CART/
cytokine kinetic profiles in PB was examined with two exter-
nal validation data sets that consisted of (i) maximal CART 
Figure 1 (a) The quantitative systems pharmacology model of anti- CD19 chimeric antigen receptor T cells (CART) in a patient with 
chronic lymphatic leukemia (CLL). BPB represent the B- cell CLL in peripheral blood (PB). CART effector (CARTE) and CART memory 
(CARTM) cells are distributed between PB (CARTEPB/CARTMPB) and tissue (CARTET/CARTMT) compartments via rate constant kin 
and kout after i.v. infusion. dCARTE and dCARTM are the death rate constants of CART from the PB. CARTE and CARTM are activated via 
activation rate aE and aM. Pendo IL6, Pendo IL10, and Pendo IFNγ are endogenous synthesis rate and dIL6, dIL10, and dIFNγ are the natural death 
rate of interleukin (IL)- 6, IL- 10, and gamma interferon (IFNγ), respectively. PIL6, PIL10, and PINFγ represent the production rate of IL- 6, 
IL- 10, and IFN γ by the activated CART, respectively. KBC is the CARTE- mediated B- cell CLL degradation rate constant in peripheral 
blood. aG and bG are the inhibitory parameters of IL10 on IFNγ production. (b) Observed CART and cytokines kinetic profiles and model 
prediction in an anti- CD19 CART-treated CLL patient. Symbol—observed CART and cytokines. Solid line—model prediction.
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peak plasma concentration (Cmax) and area under the curve 
of the time- concentration curve from t = 0 to t = 28 days 
(AUC0–28) in patients with CLL treated with CART,
13 and 
(ii) Cmax of IFNγ and CART observed in CART- treated adult 
subjects with ALL.13,14 The details of the external validation 
process is described in the Supplementary File. The final 
QSP model was then used to simulate the kinetic profiles 
of CART cells, B  cells, and pro inflammatory cytokines in 
patients with CLL with different DB and CART doses. Due to 
the limitation of the data used for QSP model development, 
the DB and CART doses up to twofold differences from the 
actual values in UPN1 and UPN3 were used in the simulation 
studies.
RESULTS AND DISCUSSION
The parameters in the final QSP model are estimated with 
good precision (percentage of coefficient of variation < 50) 
and the final QSP model is able to describe the observed 
CART kinetic and pro inflammatory cytokine profiles in pa-
tients with CLL (Figure 1b, and Table S2 and Figure S1). 
In general, CARTs differentiate and expand rapidly in the 
presence of the targeted B cell after infusion into patients 
with CLL. Then these activated CARTE target and destroy 
the B  cell CLL, resulting in rapid decline of the DB. As the 
DB decline, the CARTE decay rapidly. Depending on the 
baseline tumor burden and administered CART doses, 
this model is able to describe two distinct CART and pro 
inflammatory cytokine profiles observed in patients with 
CLL (Figure 1b). In Subject UPN1 who had 4.5- fold higher 
baseline disease burden and received 79- fold higher CART 
doses compared with subject UPN3, more CARTE are ac-
tivated and are expanded rapidly in the presence of higher 
DB and administered CART doses. Then the CARTE un-
dergo a rapid decline, as many of these cells are used to 
destroy the large DB. This rapid formation and elimination 
of activated CARTE coupled with a relatively slow formation 
of the CARTM cells15 contribute to the observed biexpo-
nential CART kinetic profiles of subject UPN1 (Figure 1b). 
In contrast, relatively low DB and administered CART doses 
are associated with a slow formation and elimination of 
the activated CARTE that contribute to the lower and less 
distinct bi- exponential CART kinetic profiles observed in 
subject UPN3 (Figure 1b). CART are a “living drug” that 
exhibit unique target- mediated drug disposition character-
istics.16–18 In contrast with most drugs that are eliminated 
from the body after administration, the CART “live and 
grow” in the presence of the target cells. As the disease 
burden remains low, the CARTE populations lose its feed-
ing sources and continue to decline and, thus, predisposing 
the patient to potential relapse. The inflammatory response 
characterized by elevation of the cytokine IL- 6, IL- 10, and 
IFN γ reaches its peak between 15 and 23 days postinfu-
sion7 and the magnitude of the cytokine elevation is highly 
correlated with the baseline DB. As the DB declines, the 
inflammation subsides1,3 (Figure 1b).
The ability of the final QSP model in describing the re-
lationships between the DB/CART doses and CART ki-
netic profiles in peripheral blood of the patients with CLL 
is examined with the external validation data set. As clearly 
shown in Figure 2a, the log- transformed Cmax and AUC0–28 
(mean ± SD) from the simulation using our QSP model is 
similar to the observed values in patients with CLL treated 
with CART.13 The quantitative effect of DB on cytokine/CART 
kinetic profiles in the peripheral blood of patients with CLL 
treated with CART has never been reported in published lit-
erature. Therefore, we decided to compare the trends of the 
simulated relationships between blood DB and Cmax of the 
CART/pro inflammatory cytokine IFNγ in peripheral blood 
of patients with CLL to the reported relationships between 
bone marrow DB and Cmax of the CART/pro inflammatory 
cytokine IFNγ in peripheral blood of patients with ALL.
13,14 
The simulated relationships between disease burden and 
Cmax of CART and IFNγ using our QSP model in peripheral 
blood of patients with CLL share a similar trend with those 
observed in patients with ALL13,14 (i.e., higher DB is asso-
ciated with higher Cmax of the CART and IFNγ; Figure S2 
and Figure S3). Taken together, these results suggested that 
the ability of our QSP model in describing the relationships 
between the DB/CART doses and CART/cytokine kinetic 
profiles are relatively consistent with the observed clinical 
findings in cancer patients treated with CART.
Simulations are performed to investigate the effect of DB 
and CART dose to the cytokines level (Figure 2b). Patients 
with a higher baseline of DB are associated with higher 
cytokine and CART Cmax after infusion and, therefore, are 
likely to experience severe CRS toxicity (Figure 2b and 
Figure S3). Hence, our results demonstrate that the devel-
oped QSP model using a well- known complex mechanistic 
interaction between CART and the inflammatory cytokine is 
sufficient to support the DB- correlated toxicity observed in 
clinical studies.1 Our results also support the clinical find-
ings that the CART dose alone has a minor effect on the 
kinetic profile of cytokines and correlates poorly with the 
degree of CRS toxicity.1,8 The observation that toxicity is 
more related with baseline DB than the administered CART 
doses is contrary to what is observed with most cancer 
chemotherapy in which the administered dose is often the 
major factor in drug- limiting toxicity, possibly due to the 
unique kinetic and dynamic characteristics of the CART in 
patients with CLL.
An activated macrophage is a major source of the IL- 6 
and can play an important role in the CRS of CART therapy.19 
However, due to lack of the kinetic profiles of the activated 
Figure 2 (a) External validation for the final quantitative systems pharmacology (QSP) model using the mean maximal concentration of 
chimeric antigen receptor T- cell (CART) peak plasma concentration (Cmax) and the mean area under the curve of the time- concentration 
curve from t = 0 to t = 28 days (AUC0–28) of the typical kinetics of CART in chronic lymphatic leukemia (CLL). Symbols and bars 
represent the predicted and observed log- transformed mean and SD values. (b) Simulated CART and cytokine kinetic profiles with 
different B- cell disease burden and anti- CD19 CART doses in a patient with CLL, CART baseline in peripheral blood (PB): 1.1 × 109 
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macrophage in our data, attempts to build the activated 
macrophages into our model are unsuccessful. Furthermore, 
other cytokines, such as monocyte chemo- attractant pro-
tein- 1 and macrophage inflammatory protein- 1β, can play 
an important role in the CRS and other toxicities associated 
with CART therapy.20 It has been shown that DB in the bone 
marrow compartment is correlated with the CART level in 
blood and, hence, can play a role in the CART kinetics.13,14 
However, the attempt to add the bone- marrow tumor com-
partment in our QSP model was unsuccessful due to lack 
of sufficient tumor burden kinetic data in the bone marrow 
for this study. Therefore, further study with more experimen-
tal data and validation is needed to refine this QSP model 
in order to increase the confidence and precision in model 
prediction.
Several mathematical models have been proposed to 
describe the kinetics of CRS in human subjects. Yiu et al.21 
developed a complex mathematical model to describe the 
kinetics of nine cytokines in six human volunteers experi-
encing CRS during the phase I clinical trial of a monoclonal 
antibody that was designed to simulate a regulatory T- cell re-
sponse. However, 90 system parameters from a set of com-
plex second- order ordinary differential equations are needed 
to be optimized in order to describe the observed kinetics 
of the 9 cytokines. Therefore, it is unlikely that this complex 
model can be supported by the limited cytokine kinetic data 
included in our study. Mathematical models have been de-
veloped to describe the complex interaction between the 
activated neutrophils/monocyte and pro inflammatory cyto-
kines in bacteria- induced sepsis, but none of these models 
can be used to investigate the CRS and CART cells in human 
subjects without major modifications.22 Recently, several 
mathematical models have been developed to describe the 
biologics of the CART.8–10 However, no clinical data are used 
to develop and validate these models,8–10 and, therefore, the 
ability of these models in describing the observed kinetics of 
cytokines and CART is questionable.
To our best knowledge, this is the first proposed QSP 
model that can describe the observed clinical data from 
patients with cancer treated with CART therapy. This QSP 
model is a valuable tool for deepening our understanding 
of how the mechanism of action connects to the clinical 
 outcomes and, therefore, may serve as an important model- 
based platform to guide the development and personalized 
dosing of the CART therapy. As shown by the well- known 
“learn- confirm” approach proposed by Sheiner,23 the QSP 
modeling and simulation can be used to learn from experi-
ence and confirm what has been learned in order to improve 
the efficiency of the clinical development of CART therapy. 
First, the clinical data collected in the early phase I data can 
be used to develop the basic QSP framework (phase I QSP 
model) to increase our understanding of how the mech-
anism of action of CART therapy connects to the toxicity 
(safety) and possible early efficacy signals in patients. Then 
the modeling and simulation results with the phase I QSP 
model are used to design a subsequent phase II study in 
order to acquire new and more diverse data to refine the 
QSP model for predicting future clinical outcomes of safety 
and efficacy. This refined phase I/II population QSP model 
should be able to quantify the effects of specific patient 
factors, such as disease and performance status, prior che-
motherapy, and genetic predisposition on the QSP model 
parameters that govern the clinical safety and efficacy in the 
studied  population. Hence, this population QSP model will 
define the exposure– response (safety and efficacy) relation-
ships that offer insights into how the phase III study protocol 
may be modified based on individual patient characteristics 
in order to decrease toxicity, increase the persistence of 
CARTE population, and potentially decrease relapse rates 
of cancer.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
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